FIVE-YEAR FINAL RESULTS OF A PHASE 3 STUDY OF CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK/SECONDARY ACUTE MYELOID LEUKEMIA (AML)

• J.E. Lancet,
• T.L. Lin,
• D. Hogge,
• S.R. Solomon,
• G.J. Schiller,
• M.J. Wieduwilt,
• R. Martin,
• S. Faderl,
• Y. Chang,
• J.E. Cortes

Affiliations

J.E. Lancet

H. Lee Moffitt Cancer Center & Research Institute, Tampa, United States

T.L. Lin

University of Kansas Medical Center, Kansas City, United States

D. Hogge

Leukemia/BMT Program of British Columbia, Vancouver, Canada

S.R. Solomon

Leukemia Program, Northside Hospital Cancer Center Institute, Atlanta, United States

G.J. Schiller

David Geffen School of Medicine at UCLA, Los Angeles, United States

M.J. Wieduwilt

University of California – San Diego Moores Cancer Center, La Jolla, United States

R. Martin

Jazz Pharmaceuticals, Oxford, United Kingdom

S. Faderl

Jazz Pharmaceuticals, Palo Alto, United States

Y. Chang

Jazz Pharmaceuticals, Palo Alto, United States

J.E. Cortes

The University of Texas MD Anderson Cancer Center, Houston, United States; Georgia Cancer Center, Augusta University, Augusta, United States